AbCellera Biologics (ABCL) Set to Announce Quarterly Earnings on Monday

Key Points

• AbCellera Biologics is scheduled to report Q3 2026 earnings after the market closes on Monday, November 9, with analysts expecting a loss of $0.17 per share and revenue of $8.41 million.
• The company’s previous quarter fell short of expectations, reporting a $0.18 per-share loss and $4.05 million in revenue versus estimates of a $0.16 loss and $7.85 million in revenue.
• Analyst sentiment is generally positive, with a “Moderate Buy” consensus rating and an average price target of $14.60, compared with the stock’s recent opening price of $11.97.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) is expected to announce its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect AbCellera Biologics to announce earnings of ($0.1706) per share and revenue of $8.41 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 5:00 PM ET.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.02). AbCellera Biologics had a negative return on equity of 17.49% and a negative net margin of 248.83%. The company had revenue of $4.05 million during the quarter, compared to analysts' expectations of $7.85 million. On average, analysts expect AbCellera Biologics to post ($0.69) EPS for the current fiscal year and ($0.82) EPS for the next fiscal year.

AbCellera Biologics Stock Performance

Shares of AbCellera Biologics stock opened at $11.97 on Monday. AbCellera Biologics has a 52-week low of $2.74 and a 52-week high of $15.02. The company's 50 day moving average price is $12.29 and its 200-day moving average price is $6.85. The stock has a market capitalization of $3.67 billion, a price-to-earnings ratio of -22.29 and a beta of 1.59.

Wall Street Analysts Forecast Growth

ABCL has been the subject of a number of recent analyst reports. Jefferies Financial Group assumed coverage on AbCellera Biologics in a report on Friday. They set a "buy" rating and a $21.00 target price for the company. UBS Group initiated coverage on AbCellera Biologics in a research report on Monday, October 12th. They issued a "buy" rating and a $18.00 target price for the company. Cantor Fitzgerald lifted their price target on shares of AbCellera Biologics from $11.00 to $12.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. began coverage on AbCellera Biologics in a research note on Tuesday, September 29th. They issued an "overweight" rating and a $17.00 target price on the stock. Finally, Stifel Nicolaus lifted their target price on shares of AbCellera Biologics from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $14.60.

AbCellera Biologics Company Profile

AbCellera Biologics Inc is a biotechnology company headquartered in Vancouver, British Columbia, that develops antibody-based medicines and provides antibody discovery services to pharmaceutical and biotechnology companies. Its platform is designed to identify therapeutic antibodies from immune cells and accelerate their progression from discovery through development.

The company combines high-throughput screening, microfluidics, single-cell analysis, automation, and artificial intelligence to evaluate large numbers of antibody candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.